Skip to main content
Fig. 3 | Gut Pathogens

Fig. 3

From: Efficacy of tailored second-line therapy of Helicobacter pylori eradication in patients with clarithromycin-based treatment failure: a multicenter prospective study

Fig. 3

H. pylori eradication rates in the TBQT group ALEB/AFEB: amoxicillin (1000 mg twice daily) + levofloxacin (500 mg once daily) or furazolidone (100 mg twice daily) + esomeprazole (20 mg twice daily) + colloidal bismuth pectin (220 mg twice daily) Lev: levofloxacin Clinical efficacies in the levofloxacin-susceptible group (ALEB therapy subgroup and AFEB therapy subgroup) and levofloxacin-resistant group (AFEB therapy subgroup) according to the ITT and PP analyses

Back to article page

Gut Pathogens

ISSN: 1757-4749